OPKO Health (OPK) Stock: Charts & Financials

OPKO Health, Inc.(OPK)

Medical - Diagnostics & Research · Miami, FL

$1.48-0.09 (-5.73%)

Delayed quote: Oct 6, 2026, 2:09 PM EDT

About OPKO Health, Inc.

OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

Miami, FL

2,275 employees

www.opko.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Phillip Frost

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	587.89M	163.58M	124.20M	148.45M	151.67M	156.81M	149.95M	183.64M	173.63M
Cost of Goods Sold	405.76M	83.56M	97.41M	103.48M	121.31M	126.85M	127.19M	98.98M	133.50M
Gross Profit	182.14M	80.02M	26.79M	44.97M	30.36M	29.96M	22.76M	84.66M	40.13M
Gross Profit Margin	31.0%	48.9%	21.6%	30.3%	20.0%	19.1%	15.2%	46.1%	23.1%
Total Operating Expenses	331.96M	86.99M	77.81M	83.29M	83.88M	89.94M	89.93M	117.80M	25.91M
Research & Development	125.22M	33.17M	29.20M	32.77M	30.08M	30.34M	30.84M	30.43M	28.77M
Selling, General & Administrative	205.85M	52.92M	48.61M	50.52M	53.80M	59.60M	59.09M	67.03M	98.20M
Operating Income (EBIT)	-149.83M	-6.97M	-51.02M	-38.32M	-53.52M	-59.98M	-67.17M	-33.14M	14.22M
Operating Margin	-25.5%	-4.3%	-41.1%	-25.8%	-35.3%	-38.3%	-44.8%	-18.0%	8.2%
Income Before Tax (EBT)	-79.85M	-13.40M	-60.96M	-46.92M	41.43M	-162.52M	-73.38M	34.98M	48.42M
Interest Income	13.07M	3.22M	3.01M	3.82M	3.02M	3.29M	4.68M	4.29M	2.93M
Interest Expense	44.99M	11.38M	10.94M	11.31M	11.36M	70.33M	15.47M	14.24M	17.36M
Other Income/Expense	69.98M	-6.43M	-9.94M	-8.60M	94.95M	-102.54M	-6.21M	68.12M	34.20M
Net Income	-72.89M	-8.42M	-54.85M	-31.26M	21.63M	-148.44M	-67.61M	14.03M	24.89M
Income Tax Expense	-6.96M	-4.98M	-6.11M	-15.66M	19.80M	-14.08M	-5.77M	20.95M	23.53M
Net Profit Margin	-12.4%	-5.1%	-44.2%	-21.1%	14.3%	-94.7%	-45.1%	7.6%	14.3%
EBITDA	-63.54M	12.00M	-28.82M	-15.94M	-30.78M	-36.95M	-43.68M	-9.10M	38.38M
EBITDA Margin	-10.8%	7.3%	-23.2%	-10.7%	-20.3%	-23.6%	-29.1%	-5.0%	22.1%
Depreciation & Amortization	86.28M	18.97M	22.20M	22.37M	22.74M	23.03M	23.49M	24.04M	24.16M
EPS Basic	-0.10	-0.01	-0.07	-0.04	0.03	-0.19	-0.10	0.02	0.04
EPS Diluted	-0.10	-0.01	-0.07	-0.04	0.03	-0.19	-0.10	0.02	0.03
Weighted Average Basic Shares	755.27M	755.27M	758.88M	765.52M	777.15M	788.01M	671.58M	694.02M	694.62M
Weighted Average Diluted Shares	755.27M	755.27M	758.88M	765.52M	779.92M	788.01M	671.58M	694.02M	695.62M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

587.89M

163.58M

124.20M

148.45M

151.67M

156.81M

149.95M

183.64M

173.63M

Cost of Goods Sold

405.76M

83.56M

97.41M

103.48M

121.31M

126.85M

127.19M

98.98M

133.50M

Gross Profit

182.14M

80.02M

26.79M

44.97M

30.36M

29.96M

22.76M

84.66M

40.13M

Gross Profit Margin

31.0%

48.9%

21.6%

30.3%

20.0%

19.1%

15.2%

46.1%

23.1%

Total Operating Expenses

331.96M

86.99M

77.81M

83.29M

83.88M

89.94M

89.93M

117.80M

25.91M

Research & Development

125.22M

33.17M

29.20M

32.77M

30.08M

30.34M

30.84M

30.43M

28.77M

Selling, General & Administrative

205.85M

52.92M

48.61M

50.52M

53.80M

59.60M

59.09M

67.03M

98.20M

Operating Income (EBIT)

-149.83M

-6.97M

-51.02M

-38.32M

-53.52M

-59.98M

-67.17M

-33.14M

14.22M

Operating Margin

-25.5%

-4.3%

-41.1%

-25.8%

-35.3%

-38.3%

-44.8%

-18.0%

8.2%

Income Before Tax (EBT)

-79.85M

-13.40M

-60.96M

-46.92M

41.43M

-162.52M

-73.38M

34.98M

48.42M

Interest Income

13.07M

3.22M

3.01M

3.82M

3.02M

3.29M

4.68M

4.29M

2.93M

Interest Expense

44.99M

11.38M

10.94M

11.31M

11.36M

70.33M

15.47M

14.24M

17.36M

Other Income/Expense

69.98M

-6.43M

-9.94M

-8.60M

94.95M

-102.54M

-6.21M

68.12M

34.20M

Net Income

-72.89M

-8.42M

-54.85M

-31.26M

21.63M

-148.44M

-67.61M

14.03M

24.89M

Income Tax Expense

-6.96M

-4.98M

-6.11M

-15.66M

19.80M

-14.08M

-5.77M

20.95M

23.53M

Net Profit Margin

-12.4%

-5.1%

-44.2%

-21.1%

14.3%

-94.7%

-45.1%

7.6%

14.3%

EBITDA

-63.54M

12.00M

-28.82M

-15.94M

-30.78M

-36.95M

-43.68M

-9.10M

38.38M

EBITDA Margin

-10.8%

7.3%

-23.2%

-10.7%

-20.3%

-23.6%

-29.1%

-5.0%

22.1%

Depreciation & Amortization

86.28M

18.97M

22.20M

22.37M

22.74M

23.03M

23.49M

24.04M

24.16M

EPS Basic

-0.10

-0.01

-0.07

-0.04

0.03

-0.19

-0.10

0.02

0.04

EPS Diluted

-0.10

-0.01

-0.07

-0.04

0.03

-0.19

-0.10

0.02

0.03

Weighted Average Basic Shares

755.27M

758.88M

765.52M

777.15M

788.01M

671.58M

694.02M

694.62M

Weighted Average Diluted Shares

755.27M

758.88M

765.52M

779.92M

788.01M

671.58M

694.02M

695.62M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	606.88M	713.14M	863.50M	1.00B	1.77B	1.44B	901.93M	990.30M
Cost of Goods Sold	478.83M	402.11M	545.37M	715.98M	1.19B	894.41M	572.48M	604.60M
Gross Profit	128.05M	311.03M	318.13M	288.22M	581.52M	541.00M	329.45M	385.70M
Gross Profit Margin	21.1%	43.6%	36.8%	28.7%	32.8%	37.7%	36.5%	38.9%
Total Operating Expenses	347.04M	463.10M	475.15M	514.47M	562.77M	483.29M	603.50M	551.90M
Research & Development	124.03M	105.21M	89.59M	73.89M	76.85M	75.32M	117.87M	135.69M
Selling, General & Administrative	223.00M	304.22M	300.56M	372.67M	468.86M	355.57M	343.31M	358.40M
Operating Income (EBIT)	-218.99M	-152.06M	-157.02M	-226.25M	18.75M	57.71M	-274.05M	-171.20M
Operating Margin	-36.1%	-21.3%	-18.2%	-22.5%	1.1%	4.0%	-30.4%	-17.3%
Income Before Tax (EBT)	-241.39M	-10.36M	-184.43M	-391.90M	-14.65M	48.20M	-304.96M	-177.27M
Interest Income	14.81M	8.43M	3.98M	1.98M	28K	152K	1.71M	1.24M
Interest Expense	108.46M	47.47M	13.51M	12.06M	18.88M	21.93M	21.52M	11.89M
Other Income/Expense	-22.41M	141.70M	-27.41M	-165.65M	-33.40M	-9.51M	-30.91M	-6.07M
Net Income	-225.68M	-53.22M	-188.86M	-328.40M	-30.14M	30.59M	-314.93M	-153.04M
Income Tax Expense	-15.71M	42.84M	4.44M	-63.50M	15.49M	17.62M	7.06M	-38.70M
Net Profit Margin	-37.2%	-7.5%	-21.9%	-32.7%	-1.7%	2.1%	-34.9%	-15.5%
EBITDA	-127.36M	-53.89M	-51.72M	-117.60M	97.47M	143.08M	-180.25M	-73.85M
EBITDA Margin	-21.0%	-7.6%	-6.0%	-11.7%	5.5%	10.0%	-20.0%	-7.5%
Depreciation & Amortization	91.63M	98.18M	105.30M	108.66M	78.72M	85.36M	93.81M	97.34M
EPS Basic	-0.30	-0.08	-0.25	-0.46	-0.05	0.05	-0.53	-0.27
EPS Diluted	-0.30	-0.08	-0.25	-0.46	-0.05	0.05	-0.53	-0.27
Weighted Average Basic Shares	751.13M	694.02M	751.77M	719.06M	648.08M	640.65M	595.45M	563.14M
Weighted Average Diluted Shares	751.13M	694.02M	751.77M	719.06M	648.08M	640.65M	595.45M	566.67M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

606.88M

713.14M

863.50M

1.00B

1.77B

1.44B

901.93M

990.30M

Cost of Goods Sold

478.83M

402.11M

545.37M

715.98M

1.19B

894.41M

572.48M

604.60M

Gross Profit

128.05M

311.03M

318.13M

288.22M

581.52M

541.00M

329.45M

385.70M

Gross Profit Margin

21.1%

43.6%

36.8%

28.7%

32.8%

37.7%

36.5%

38.9%

Total Operating Expenses

347.04M

463.10M

475.15M

514.47M

562.77M

483.29M

603.50M

551.90M

Research & Development

124.03M

105.21M

89.59M

73.89M

76.85M

75.32M

117.87M

135.69M

Selling, General & Administrative

223.00M

304.22M

300.56M

372.67M

468.86M

355.57M

343.31M

358.40M

Operating Income (EBIT)

-218.99M

-152.06M

-157.02M

-226.25M

18.75M

57.71M

-274.05M

-171.20M

Operating Margin

-36.1%

-21.3%

-18.2%

-22.5%

1.1%

4.0%

-30.4%

-17.3%

Income Before Tax (EBT)

-241.39M

-10.36M

-184.43M

-391.90M

-14.65M

48.20M

-304.96M

-177.27M

Interest Income

14.81M

8.43M

3.98M

1.98M

28K

152K

1.71M

1.24M

Interest Expense

108.46M

47.47M

13.51M

12.06M

18.88M

21.93M

21.52M

11.89M

Other Income/Expense

-22.41M

141.70M

-27.41M

-165.65M

-33.40M

-9.51M

-30.91M

-6.07M

Net Income

-225.68M

-53.22M

-188.86M

-328.40M

-30.14M

30.59M

-314.93M

-153.04M

Income Tax Expense

-15.71M

42.84M

4.44M

-63.50M

15.49M

17.62M

7.06M

-38.70M

Net Profit Margin

-37.2%

-7.5%

-21.9%

-32.7%

-1.7%

2.1%

-34.9%

-15.5%

EBITDA

-127.36M

-53.89M

-51.72M

-117.60M

97.47M

143.08M

-180.25M

-73.85M

EBITDA Margin

-21.0%

-7.6%

-6.0%

-11.7%

5.5%

10.0%

-20.0%

-7.5%

Depreciation & Amortization

91.63M

98.18M

105.30M

108.66M

78.72M

85.36M

93.81M

97.34M

EPS Basic

-0.30

-0.08

-0.25

-0.46

-0.05

0.05

-0.53

-0.27

EPS Diluted

-0.30

-0.08

-0.25

-0.46

-0.05

0.05

-0.53

-0.27

Weighted Average Basic Shares

751.13M

694.02M

751.77M

719.06M

648.08M

640.65M

595.45M

563.14M

Weighted Average Diluted Shares

751.13M

694.02M

751.77M

719.06M

648.08M

640.65M

595.45M

566.67M

Income Statement

Quarterly Income Statement (USD)

Annual Income Statement (USD)